<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02840786</url>
  </required_header>
  <id_info>
    <org_study_id>XuanwuH16</org_study_id>
    <nct_id>NCT02840786</nct_id>
  </id_info>
  <brief_title>Clinical Study of Stent Versus Direct Atherectomy to Treat Arteriosclerosis Occlusive Disease of Lower Extremity</brief_title>
  <official_title>Occlusive Disease of Lower Extremity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study comparing stent and plaque excision systems in treatment of
      Arteriosclerosis occlusive disease of lower extremity (superficial femoral or popliteal
      artery)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized study comparing stent and plaque excision systems in treatment of
      Arteriosclerosis occlusive disease of lower extremity (superficial femoral or popliteal
      artery)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-month Primary Patency Rate</measure>
    <time_frame>12 months</time_frame>
    <description>systolic velocity ratio &gt;2.4 as measured by Duplex ultrasound.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-month Limb Salvage Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Limb Salvage is defined as the freedom from secondary major amputation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Index Limb Ischemia at 6-month Follow up</measure>
    <time_frame>6 months</time_frame>
    <description>Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index Limb Ischemia at 12-month Follow up</measure>
    <time_frame>12 months</time_frame>
    <description>Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events at 12-month Post Procedure</measure>
    <time_frame>12 months</time_frame>
    <description>Major adverse events included death, index limb ischemia, index limb amputation, clinically driven target lesion revascularization , and significant embolic events, which were defined as causing end-organ damage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>Intervention: Stents</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stents group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention: Atherectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Direct Atherectomy group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>plaque excision system</intervention_name>
    <arm_group_label>Intervention: Atherectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stent</intervention_name>
    <arm_group_label>Intervention: Stents</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Provides written informed consent Willing to comply with follow-up evaluations at specified
        times Has claudication or rest pain due to peripheral arterial disease Disease located
        within the femoropopliteal artery Patient has a de novo or restenotic lesion(s) with &gt;50%
        stenosis documented angiographically and no prior stent in the target lesion.

        Patient has symptoms of peripheral arterial disease classified as Rutherford Category 2 or
        greater.

        Exclusion Criteria:

        Previously implanted stent(s) or stent graft(s) in target leg Life expectancy less than 12
        months Has any planned surgical or endovascular intervention of target vessel 30 days
        before or after index procedure Thrombophlebitis, uremia, or deep venous thrombus, within
        past 30 days. Receiving dialysis or immunosuppressant therapy. Recent stroke within past 90
        days. Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®) or
        ticlopidine (Ticlid®), heparin, Nitinol (nickel titanium), contrast agent, that cannot be
        medically managed.

        Tissue loss due to ischemic disease (Rutherford/Becker category 5 or 6) Serum creatinine
        level &gt;/= 2.5 mg/dl at time of screening visit Known or suspected active infection at the
        time of the procedure Bleeding diathesis Patient is unwilling or unable to comply with
        procedures specified in the protocol or has difficulty or inability to return for follow-up
        visits as specified by the protocol.

        Patient is known to be pregnant, incarcerated, mentally incompetent, and/or alcohol or drug
        abuser.

        Patient is currently participating in any other investigational drug or medical device
        study that has not completed primary endpoint(s) evaluation or clinically interferes with
        the endpoints from this study or future participation in such studies prior to the
        completion of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>yang Li, M.D.</last_name>
    <phone>18810432268</phone>
    <email>liyang0603@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yong quan Gu, M.D.</last_name>
    <phone>15901598209</phone>
    <email>15901598209@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gu Yong Quan</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian ming Guo, M.D.</last_name>
      <phone>13146369562</phone>
      <email>guojianming@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Yong quan Gu, M.D.</last_name>
      <phone>15901598209</phone>
      <email>15901598209@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stents</keyword>
  <keyword>atherectomy</keyword>
  <keyword>femoral artery</keyword>
  <keyword>popliteal artery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

